The chief of Cancer Immunotherapy at Rutgers Cancer Institute of New Jersey discussed unmet needs with cellular therapies in metastatic epithelial cancer.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Christian S. Hinrichs, MD, chief, Cancer Immunotherapy, and co-director, Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence, and program co-leader, Cancer Metabolism and Growth Program, Rutgers Cancer Institute of New Jersey, and professor of Medicine, Rutgers Robert Wood Johnson Medical School, about unmet needs with cellular therapies in metastatic epithelial cancer.
Many patients with epithelial cancer are diagnosed at an advanced stage and curative therapies are not available for patients with metastatic disease. This represents the biggest unmet need in epithelial cancer, and therefore with cell therapy in the indication. Although some patients can be cured, it is rare which makes this a significantly challenging disease to manage, Hinrichs said.
Research efforts are trying to develop better treatments, and especially trying to develop curative therapies for patients with metastatic epithelial cancers, Hinrichs concluded.